Scienture Holdings, Inc.

(a) During the quarter ended June 30, 2026, there was no information required to be disclosed in a report on Form 8-K which was not disclosed in a report on Form 8-K.

(b) During the quarter ended June 30, 2026, there were no material changes to the procedures by which stockholders may recommend nominees to our Board.

(c) During the quarter ended June 30, 2026, Dr. Shankar Hariharan, our Executive Chairman and Co-Chief Executive Officer, entered into a “Rule 10b5-1 trading arrangement” (the “Sales Plan”) as that term is defined in Item 408(a) of Regulation S-K. The Sales Plan was adopted on June 3, 2026, and was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act. In accordance with each Sales Plan, a broker is authorized to begin selling Common Stock pursuant to the Sales Plan beginning on November 2, 2026. The Sales Plan is scheduled to terminate on January 8, 2027 (unless terminated earlier in accordance with its terms). No sales of Common Stock may be affected at a price less than $1.00 per share, and the total number of shares that may be sold cannot exceed 150,000.

No other officer or director adopted orterminated (1) a plan, contract, or set of instructions intended to by covered by the 10b5-1 affirmative defense or (2) a written trading arrangement as defined in Item 408(c) of Regulation S-K.